These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 26748161)

  • 1. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients.
    Issa NC; Marty FM; Leblebjian H; Galar A; Shea MM; Antin JH; Soiffer RJ; Baden LR
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):285-7. PubMed ID: 24269706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella-Zoster Virus Reactivation After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation, Single-Center Experience of Acyclovir Prophylaxis.
    Arıcı G; Ince E; Ince E; Ileri T; Ciftci E; Dogu F; Ozdemir H; Cakmakli HF; Ertem M
    Pediatr Transplant; 2024 Aug; 28(5):e14819. PubMed ID: 38924278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.
    Sasadeusz J; Prince HM; Schwarer A; Szer J; Stork A; Bock HL; Povey M; Nicholson O; Innis BL
    Transpl Infect Dis; 2014 Dec; 16(6):1024-31. PubMed ID: 25272081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
    BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of varicella vaccine: a 10-year review.
    Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
    J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
    Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
    Boeckh M; Kim HW; Flowers ME; Meyers JD; Bowden RA
    Blood; 2006 Mar; 107(5):1800-5. PubMed ID: 16282339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
    Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
    Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation.
    Leung AY; Chow HC; Kwok JS; Lui CK; Cheng VC; Yuen KY; Lie AK; Liang R
    Bone Marrow Transplant; 2007 Jun; 39(11):661-5. PubMed ID: 17417658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study.
    Ljungman P; Wang FZ; Nilsson C; Solheim V; Linde A
    Support Care Cancer; 2003 Nov; 11(11):739-41. PubMed ID: 13680325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).
    Chou JF; Kernan NA; Prockop S; Heller G; Scaradavou A; Kobos R; Knowles MA; Papadopoulos EB; Casson A; Copeland C; Torok-Castanza J; Zakak N; Ruggiero J; Small TN
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1708-13. PubMed ID: 21664979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
    Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
    J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.
    Hata A; Asanuma H; Rinki M; Sharp M; Wong RM; Blume K; Arvin AM
    N Engl J Med; 2002 Jul; 347(1):26-34. PubMed ID: 12097537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.
    Parrino J; McNeil SA; Lawrence SJ; Kimby E; Pagnoni MF; Stek JE; Zhao Y; Chan IS; Kaplan SS
    Vaccine; 2017 Mar; 35(14):1764-1769. PubMed ID: 28268074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.
    Weinmann S; Chun C; Schmid DS; Roberts M; Vandermeer M; Riedlinger K; Bialek SR; Marin M
    J Infect Dis; 2013 Dec; 208(11):1859-68. PubMed ID: 23922376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.